RT Journal Article
T1 Extended Infusion of β-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study.
A1 Bartoletti, Michele
A1 Giannella, Maddalena
A1 Lewis, Russell E
A1 Caraceni, Paolo
A1 Tedeschi, Sara
A1 Paul, Mical
A1 Schramm, Christoph
A1 Bruns, Tony
A1 Merli, Manuela
A1 Cobos-Trigueros, Nazaret
A1 Seminari, Elena
A1 Retamar, Pilar
A1 Muñoz, Patricia
A1 Tumbarello, Mario
A1 Burra, Patrizia
A1 Torrani Cerenzia, Maria
A1 Barsic, Bruno
A1 Calbo, Ester
A1 Maraolo, Alberto Enrico
A1 Petrosillo, Nicola
A1 Galan-Ladero, Maria Angeles
A1 D'Offizi, Gianpiero
A1 Zak-Doron, Yael
A1 Rodriguez-Baño, Jesus
A1 Baldassarre, Maurizio
A1 Verucchi, Gabriella
A1 Domenicali, Marco
A1 Bernardi, Mauro
A1 Viale, Pierluigi
A1 ESGBIS/BICHROME study group, 
K1 bloodstream infection
K1 continuous infusion
K1 liver cirrhosis
K1 β-lactam antibiotics
AB We analyzed the impact of continuous/extended infusion (C/EI) vs intermittent infusion of piperacillin-tazobactam (TZP) and carbapenems on 30-day mortality of patients with liver cirrhosis and bloodstream infection (BSI). The BICRHOME study was a prospective, multicenter study that enrolled 312 cirrhotic patients with BSI. In this secondary analysis, we selected patients receiving TZP or carbapenems as adequate empirical treatment. The 30-day mortality of patients receiving C/EI or intermittent infusion of TZP or carbapenems was assessed with Kaplan-Meier curves, Cox-regression model, and estimation of the average treatment effect (ATE) using propensity score matching. Overall, 119 patients received TZP or carbapenems as empirical treatment. Patients who received C/EI had a significantly lower mortality rate (16% vs 36%, P = .047). In a Cox-regression model, the administration of C/EI was associated with a significantly lower mortality (hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.11-0.936; P = .04) when adjusted for severity of illness and an ATE of 25.6% reduction in 30-day mortality risk (95% CI, 18.9-32.3; P  C/EI of beta-lactams in cirrhotic patients with BSI may improve outcomes and facilitate earlier discharge.
YR 2019
FD 2019
LK http://hdl.handle.net/10668/13426
UL http://hdl.handle.net/10668/13426
LA en
DS RISalud
RD Apr 18, 2025